1-11 of 11
Karin Havenith
Close
Sort by
Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano
Journal: Blood
Blood (2023) 142 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2023-179977
Published: 2023
Journal Articles

CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni
Journal: Blood
Blood (2022) 140 (Supplement 1): 9548–9550.
https://doi.org/10.1182/blood-2022-159626
Published: 2022
Journal Articles

Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)

Francesco Vallania, Victoria Cheung, Michael D. Zamba, Joyce Liu, Amit Pasupathy, Hayley Donnella, Mitch Bailey, Maggie Louie, Jimmy Lin, Karin Havenith, Yajuan Qin, Serafino Pantano, Jens Wuerthner, Patrick H van Berkel
Journal: Blood
Blood (2022) 140 (Supplement 1): 3551–3552.
https://doi.org/10.1182/blood-2022-168993
Published: 2022
Journal Articles

Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties

Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Caetano-Silva, Winston Vetharoy, Ian Kirby, Francesca Zammarchi, Karin Havenith, Patrick H van Berkel, Claire Booth, H Bobby Gaspar, Adrian J. Thrasher, Kerry Chester, Persis J Amrolia
Journal: Blood
Blood (2022) 140 (Supplement 1): 10211–10212.
https://doi.org/10.1182/blood-2022-162390
Published: 2022
Journal Articles

CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Jerzy Dyczkowski, Alex F. Herrera, Carmelo Carlo-Stella, Pier Luigi Zinzani, Marie Toukam, Hans G. Cruz, Karin Havenith, Joseph Boni, Jens Wuerthner, Serafino Pantano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9306–9308.
https://doi.org/10.1182/blood-2022-157748
Published: 2022
Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Journal: Blood
Blood (2021) 137 (19): 2634–2645.
https://doi.org/10.1182/blood.2020007512
Published: 2021
Includes: Supplemental data
Journal Articles

Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Joseph Boni, Karin Havenith, Mehdi Hamadani, MD, Paolo F Caimi, MD, Katie Anderson, Tim Kopotsha, Hans G Cruz, Jens Wuerthner
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137011
Published: 2020
Journal Articles

Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Owen Anthony O'Connor, MD, Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Erin Reid, MD, Jay Feingold, MD PhD, Karin Havenith, PhD, Shui He, PhD, Diane R Mould, PhD, Immanuel Freedman, PhD, Joseph Boni, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2543.
https://doi.org/10.1182/blood.V130.Suppl_1.2543.2543
Published: 2017
Journal Articles

hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.

Francesca Zammarchi, PhD, Simon Corbett, Lauren Adams, Maria Mellinas-Gomez, PhD, Peter Tyrer, PhD, Sandamali Dissanayake, Simone Sims, Karin Havenith, PhD, Simon Chivers, PhD, David G Willimas, PhD, Philip W Howard, PhD, John A. Hartley, PhD, Patrick van Berkel, PhD
Journal: Blood
Blood (2016) 128 (22): 4176.
https://doi.org/10.1182/blood.V128.22.4176.4176
Published: 2016
Journal Articles

Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies

Francesca Zammarchi, PhD, David G. Williams, PhD, Lauren Adams, Karin Havenith, PhD, Simon Chivers, PhD, Francois D'Hooge, PhD, Philip W. Howard, PhD, John A. Hartley, PhD, Patrick H. van Berkel, PhD
Journal: Blood
Blood (2015) 126 (23): 1564.
https://doi.org/10.1182/blood.V126.23.1564.1564
Published: 2015
Journal Articles

Features of Macrophage Differentiation Induced by p19 INK4d , a Specific Inhibitor of Cyclin D–Dependent Kinases

Masashi Adachi, Martine F. Roussel, Karin Havenith, Charles J. Sherr
Journal: Blood
Blood (1997) 90 (1): 126–137.
https://doi.org/10.1182/blood.V90.1.126
Published: 1997